Country: Canada
Language: English
Source: Health Canada
MYCOPHENOLIC ACID (MYCOPHENOLATE SODIUM)
APOTEX INC
L04AA06
MYCOPHENOLIC ACID
180MG
TABLET (ENTERIC-COATED)
MYCOPHENOLIC ACID (MYCOPHENOLATE SODIUM) 180MG
ORAL
120
Prescription
IMMUNOSUPPRESSIVE AGENTS
Active ingredient group (AIG) number: 0150521001; AHFS:
APPROVED
2014-05-06
_Pr_ _APO-MYCOPHENOLIC ACID (_Mycophenolic acid delayed-release tablets) _ Page 1 of 43 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-MYCOPHENOLIC ACID Mycophenolic acid delayed-release tablets Delayed-release tablets, 180 mg and 360 mg mycophenolic acid (as mycophenolate sodium), Oral USP Immunosuppressant ATC code: L04AA06 APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: MAY 06, 2014 Date of Revision: NOV 10, 2022 Submission Control Number: 264756 _Pr_ _APO-MYCOPHENOLIC ACID (_Mycophenolic acid delayed-release tablets) _ Page 2 of 43 _ RECENT MAJOR LABEL CHANGES None at the time of authorisation TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics ......................................................................................................... 4 1.2 Geriatrics.......................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................... 4 4 DOSAGE AND ADMINISTRATION.................................................................................... 5 4.1 Dosing Considerations ...................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment................................. Read the complete document